Adenine base editing of CFTR using receptor targeted nanoparticles restores function to G542X cystic fibrosis airway epithelial cells
Open Access
- 7 April 2025
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-16
Abstract
The cystic fibrosis (CF) causing variant G542X harbours a premature translation stop signal in the cystic fibrosis transmembrane conductance regulator ( CFTR ) mRNA. This results in nonsense-mediated decay and loss of functional CFTR protein which leads to defective anion transport and the development of CF disease pathology. Currently available CF modulator therapies cannot be used to treat this variant. We used an adenine base editor (ABE8e Cas9) and guide RNA (sgRNA)/enhanced green fluorescent protein (EGFP) plasmids encapsulated in receptor targeted nanoparticles (RTN), delivered to Bmi-1 transduced basal human CF airway epithelial cells harbouring the homozygous CFTR G542X variant, to convert the stop codon to G542R, a variant which is amenable to modulator therapy. ABE resulted in 17% of alleles edited to G542R and further selection of GFP fluorescent cells by FACS liberated a population with 52% G542R edited alleles with no editing of neighbouring adenines (A) and few off target edits using a gRNA homology-based approach. In cells differentiated at air–liquid-interface (ALI), 17% and 52% editing of CFTR G542X increased mRNA abundance. 52% editing alone or 17% and 52% editing of CFTR G542X plus treatment with CFTR modulators (VX-445/VX-661/VX-770; ETI/Trikafta/Kaftrio) increased epithelial CFTR protein expression, CFTR protein band C abundance, CFTR 172 inhibitable anion transport, and changes in airway surface liquid height and pH in response to vasoactive intestinal peptide (VIP) stimulation. Epithelial scratch repair speed and directionality was also improved. These data provide proof-of-concept that ABE of G542X to G542R in human CF airway epithelial cells could provide a feasible therapy for this variant. Graphical abstractKeywords
Funding Information
- Cystic Fibrosis Trust (Strategic Research Centre Award (SRC 020))
- Cystic Fibrosis Foundation (Strategic Research Centre Award (SRC 020))
This publication has 52 references indexed in Scilit:
- Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cellsCell Reports Medicine, 2024
- Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivoEuropean Journal of Pharmaceutics and Biopharmaceutics, 2024
- Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editingMolecular Therapy - Methods & Clinical Development, 2023
- Expression of gain-of-function CFTR in cystic fibrosis airway cells restores epithelial function better than wild-type or codon-optimized CFTRMolecular Therapy - Methods & Clinical Development, 2023
- Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locusMolecular Therapy, 2022
- Loss of ciliated cells and altered airway epithelial integrity in cystic fibrosisJournal of Cystic Fibrosis, 2021
- Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosisInternational Forum of Allergy & Rhinology, 2020
- CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproductsJournal of Cystic Fibrosis, 2018
- Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorderDrug Discovery Today: Disease Mechanisms, 2007
- Efficient transfection of non‐proliferating human airway epithelial cells with a synthetic vector systemThe Journal of Gene Medicine, 2004